Nammi Therapeutics, Inc., a Los Angeles, CA-based immuno-oncology firm, acquired $1M in funding dedication by the Myeloma Funding Fund (MIF).
The funding was a part of a $30M Sequence B financing spherical.
Led by David Stover, Ph.D., President and CEO, Nammi Therapeutics is an immuno-oncology firm growing platforms and merchandise that selectively activate anti-tumor immunity inside the tumor microenvironment whereas minimizing systemic activation. By lowering systemic activation of the immune system, the corporate expects to enhance security and improve the flexibility to mix a number of immune modulators. Along with the MIC platform, Nammi has additionally developed a nanoparticle platform to ship Immune Modulating Prodrugs (IMPs) utilizing their Nammisome expertise.
The funding got here previous to the deliberate begin of a first-in-human Section 1 examine of its lead program, QXL138AM, in sufferers with domestically superior unresectable and/or metastatic strong tumors and a number of myeloma.
QXL138AM is a Masked Immunocytokine (MIC) comprised of a masked interferon alpha (IFNa) fused to an antibody that targets the CD138 protein on the floor of the tumor cells. As soon as QXL138AM binds to the tumor cell, proteases on the cell floor cleave the masks off of the IFNa permitting it to bind its receptor. Activation of the IFNa receptor complicated induces direct killing of tumor cells along with activating innate and adaptive anti-tumor immunity. Preclinical information has demonstrated vital anti-tumor efficacy throughout greater than 10 tumor sorts together with a number of myeloma the place full regression at doses as little as 0.1 mg/kg have been noticed. Nammi has secured Orphan Drug Designation in a number of myeloma from the FDA on the power of this information.
FinSMEs
06/08/2024
